Skip to main content
. Author manuscript; available in PMC: 2010 Sep 1.
Published in final edited form as: Epilepsia. 2009 Feb 26;50(9):2117–2122. doi: 10.1111/j.1528-1167.2009.02048.x

Fig. 2. Effects of bumetanide on kindling progression.

Fig. 2

In P11 animals (A), pretreatment with bumetanide (0.5 mg/kg) delayed the occurrence, and reduced the number of stage 4 seizures; neither of the analyzed indices was modified in groups of P14 (B) and P21 (C) rats. On A-C data are presented as Mean±SEM; asterisk on A- p<0.05 vs. Control (Mann-Whitney test). D: Plot of stage 4-5 seizure count in individual animals of three ages. For each animal, the effect of bumetanide is expressed as percent of the mean number of stage 4-5 seizures in control groups (Y-axis). Color-coded numbers under the X-axis correspond to respective data points for each animal and age. Arrows point to those subjects, in which bumetanide pretreatment reduced number of stage 4-5 seizures by 2 standard deviations or more from mean values in age-matched control groups.